(Q58074723)

https://api.crossref.org/works/10.1586%2FERM.10.109

American Society of Transplantation recommendations for screening, monitoring and reporting of infectious complications in immunosuppression trials in recipients of organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Valacyclovir for the prevention of cytomegalovirus disease after renal transplantation. International Valacyclovir Cytomegalovirus Prophylaxis Transplantation Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Evidence for a bidirectional relationship between cytomegalovirus replication and acute graft-versus-host disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Changes in the natural history of cytomegalovirus retinitis following the introduction of highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cytomegalovirus prophylaxis and graft outcome in solid organ transplantation: a collaborative transplant study report

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

The impact of cytomegalovirus serostatus of donor and recipient before hematopoietic stem cell transplantation in the era of antiviral prophylaxis and preemptive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Improvement in long-term renal graft survival due to CMV prophylaxis with oral ganciclovir: results of a randomized clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

International consensus guidelines on the management of cytomegalovirus in solid organ transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cost-effectiveness of a new combined immunosuppressive and anti-infectious regimen in kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

The efficacy and safety of 200 days valganciclovir cytomegalovirus prophylaxis in high-risk kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cytomegalovirus disease among donor-positive/recipient-negative lung transplant recipients in the era of valganciclovir prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Late-onset cytomegalovirus disease in patients with solid organ transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

What is the impact of late-onset cytomegalovirus disease after valganciclovir prophylaxis in kidney transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Efficacy and safety of valganciclovir vs. oral ganciclovir for prevention of cytomegalovirus disease in solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Delayed-onset primary cytomegalovirus disease and the risk of allograft failure and mortality after kidney transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

CMV infections after hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

How we treat cytomegalovirus in hematopoietic cell transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Immunobiology of human cytomegalovirus: from bench to bedside.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Human cytomegalovirus: clinical aspects, immune regulation, and emerging treatments.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Sensitive detection of human cytomegalovirus peptide-specific cytotoxic T-lymphocyte responses by interferon-gamma-enzyme-linked immunospot assay and flow cytometry in healthy individuals and in patients after allogeneic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Natural history of opportunistic disease in an HIV-infected urban clinical cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Plasma cytomegalovirus DNA, pp65 antigenaemia and a low CD4 cell count remain risk factors for cytomegalovirus disease in patients receiving highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cytomegalovirus disease in the era of highly active antiretroviral therapy (HAART).

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Clinical utility of cytomegalovirus viral load testing for predicting CMV disease in D+/R- solid organ transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Clinical utility of cytomegalovirus (CMV) serology testing in high-risk CMV D+/R- transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Clinical utility of measuring T-cell immunity to CMV in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Ex vivo monitoring of human cytomegalovirus-specific CD8+ T-cell responses using QuantiFERON-CMV.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cell-mediated immunity to predict cytomegalovirus disease in high-risk solid organ transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Linking CMV serostatus to episodes of CMV reactivation following lung transplantation by measuring CMV-specific CD8+ T-cell immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Human cytomegalovirus (CMV)-specific CD8+ T cell responses are reduced in HIV-infected individuals with a history of CMV disease despite CD4+ T cell recovery

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence.

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

A prospective longitudinal analysis of cytomegalovirus (CMV)-specific CD4+ and CD8+ T cells in kidney allograft recipients at risk of CMV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cytomegalovirus-specific T-cell responses and viral replication in kidney transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Levels of virus-specific CD4 T cells correlate with cytomegalovirus control and predict virus-induced disease after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Protection from cytomegalovirus after transplantation is correlated with immediate early 1-specific CD8 T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cellular immune responses to cytomegalovirus in renal transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Cytomegalovirus-specific IFN-γ production is associated with protection against cytomegalovirus reactivation in HIV-infected patients on highly active antiretroviral therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Functional impairment of cytomegalovirus specific CD8 T cells predicts high-level replication after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Immune monitoring with iTAg MHC Tetramers for prediction of recurrent or persistent cytomegalovirus infection or disease in allogeneic hematopoietic stem cell transplant recipients: a prospective multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the antigen-specific CD8(+) T-cell response

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

The Influence of Innate Immunity Gene Receptors Polymorphisms in Renal Transplant Infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109

Association Between Mannose-Binding Lectin Deficiency and Cytomegalovirus Infection After Kidney Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1586%2FERM.10.109